MAPT and Alzheimer disease: While such responses can be protective against Aβ plaques and/or tau aggregates in the early stage [137], the neuroinflammation may also be detrimental to patients by neurotoxic inflammatory mediators leading to brain dysfunctions within the neocortex and hippocampus in the late stage of AD [138].